Week 0 | week 4 | week 8 | ||
---|---|---|---|---|
JKOM 1 in all subjects (mm) | Placebo | 35.73 ± 19.02 | −2.31 ± 18.94 | −13.12 ± 21.07 |
Active | 41.20 ± 21.96 | −11.10 ± 25.61 | −11.77 ± 28.29 | |
p | 0.40 | 0.17 | 0.81 | |
JKOM 1 in subjects whose VAS score was better (mm) | Placebo | 32.77 ± 16.92 | −0.92 ± 18.33 | −16.00 ± 18.86 |
Active | 30.93 ± 22.39 | −3.80 ± 30.99 | −4.20 ± 34.56 | |
p | 0.55 | 0.98 | 0.26 | |
JKOM 1 in subjects whose VAS score was worst (mm) | Placebo | 38.69 ± 21.17 | −3.69 ± 20.18 | −10.23 ± 23.48 |
Active | 51.47 ± 16.50 | −18.40 ± 16.86 | −19.33 ± 18.46 | |
p | 0.10 | 0.07 | 0.14 | |
JKOM 2 - 5 in all subjects (points) | Placebo | 20.46 ± 9.30 | −3.73 ± 7.75 | −5.88 ± 9.17 |
Active | 21.27 ± 7.52 | −4.10 ± 6.04 | −7.20 ± 7.44 | |
p | 0.66 | 0.70 | 0.69 | |
JKOM 2 - 5 in subjects whose VAS score was better (points) | Placebo | 17.54 ± 7.50 | −2.85 ± 8.72 | −7.92 ± 9.13 |
Active | 17.33 ± 5.64 | −1.33 ± 6.80 | −3.07 ± 5.91 | |
p | 0.835 | 0.503 | 0.059 | |
JKOM 2 - 5 in subjects whose VAS score was worst (points) | Placebo | 23.38 ± 10.26 | −4.62 ± 6.90 | −3.85 ± 9.09 |
Active | 25.20 ± 7.23 | −6.87 ± 3.58 | −11.33 ± 6.58 | |
p | 0.64 | 0.15 | 0.016* | |
Knee pain at rest (mm) | Placebo | 68.15 ± 27.87 | 10.23 ± 31.99 | 10.73 ± 25.56 |
Active | 69.17 ± 26.46 | 6.13 ± 24.64 | 4.40 ± 38.53 | |
p | 0.67 | 0.71 | 0.84 | |
Knee pain at walking (mm) | Placebo | 56.65 ± 23.32 | 12.12 ± 30.72 | 15.58 ± 25.00 |
Active | 51.53 ± 24.33 | 14.43 ± 20.34 | 14.80 ± 32.77 | |
p | 0.38 | 0.99 | 0.77 | |
Knee pain while climbing up/down stairs (mm) | Placebo | 43.00 ± 21.88 | 15.31 ± 27.51 | 18.00 ± 25.60 |
Active | 43.30 ± 24.69 | 13.30 ± 23.83 | 13.63 ± 29.48 | |
p | 0.91 | 0.73 | 0.63 |